학술논문
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
Document Type
Article
Author
Jhaveri, K.; Eli, L.D.; Wildiers, H.; Hurvitz, S.A.; Guerrero-Zotano, A.; Unni, N.; Brufsky, A.; Park, H.; Waisman, J.; Yang, E.S.; Spanggaard, I.; Reid, S.; Burkard, M.E.; Vinayak, S.; Prat, A.; Arnedos, M.; Bidard, F.-C.; Loi, S.; Crown, J.; Bhave, M.; Piha-Paul, S.A.; Suga, J.M.; Chia, S.; Saura, C.; Garcia-Saenz, J.Á.; Gambardella, V.; de Miguel, M.J.; Gal-Yam, E.N.; Raphael, A.; Stemmer, S.M.; Ma, C.; Hanker, A.B.; Ye, D.; Goldman, J.W.; Bose, R.; Peterson, L.; Bell, J.S.K.; Frazier, A.; DiPrimeo, D.; Wong, A.; Arteaga, C.L.; Solit, D.B.
Source
In Annals of Oncology October 2023 34(10):885-898
Subject
Language
ISSN
0923-7534